Paige.AI Receives FDA’s Breakthrough Designation for its Artificial Intelligence in Pathology

 Paige.AI Receives FDA’s Breakthrough Designation for its Artificial Intelligence in Pathology

Paige.AI Receives FDA’s Breakthrough Designation for its Artificial Intelligence in Pathology

Shots:

  • FDA grants BT designation to Paige.AI to develop AI in computational pathology for the diagnosis and treatment of cancer including prostate cancer
  • The FDA’s BT designation is granted for technologies that provide effective diagnosis and treatment for life-threatening diseases
  • Paige.AI is based on Fuch’s technology, works with the de-identified dataset to develop AI portfolio targeting multiple cancer across the world

Click here to read full press release/ article | Ref: Business Wire | Image: Medium

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post